<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349945</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2010-020240-35</org_study_id>
    <nct_id>NCT02349945</nct_id>
  </id_info>
  <brief_title>FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy</brief_title>
  <official_title>Significance of the FSH Receptor Polymorphism p.N680S for the Efficacy of FSH Therapy of Idiopathic Male Infertility: a Pharmacogenetic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda USL Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Halle Medical Faculty</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda USL Modena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CONDITION: Idiopathic male infertility In men with idiopathic infertility, the sperm DNA&#xD;
      fragmentation index (DFI) within 12 weeks of FSH therapy and 12 weeks follow-up improves&#xD;
      depending on the FSHR genotype as assessed by the non-synonymous SNP rs6166 (wild type or&#xD;
      p.N680S).&#xD;
&#xD;
      This is a phase II b, multicenter, prospective, open label, one arm, clinical trial&#xD;
      stratified according to the patient's genotype.&#xD;
&#xD;
      INTERVENTION: FSH therapy (150 I.U. sc every other day for 12 weeks) in infertile men who are&#xD;
      homozygous for the wild-type FSHR or the p.N680S allele of the FSHR. Duration of intervention&#xD;
      per patient: 12 weeks&#xD;
&#xD;
      Primary efficacy endpoint: Sperm DFI. Number of patients with an improvement in DFI &gt; 60% Key&#xD;
      secondary endpoint(s): pregnancy, semen parameters, serum levels of inhibin B and AMH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male factor infertility is responsible for about 50% of cases of involuntary couple&#xD;
      infertility and remains idiopathic in about half of the cases. At present, there are no&#xD;
      consistently effective treatments for male idiopathic infertility. Since follicle-stimulating&#xD;
      hormone (FSH) is fundamental for spermatogenesis, recombinant hFSH is empirically used for&#xD;
      male infertility treatment. The response to FSH, however, is highly variable and while sperm&#xD;
      parameters improve in some patients, about 50% of the subjects do not clearly respond to FSH.&#xD;
      Several studies were performed in the past and a recent Cochrane meta-analysis showed that&#xD;
      FSH treatment of male idiopathic infertility overall significantly improves pregnancy rate.&#xD;
      Nevertheless, no predictive marker of response to FSH, allowing a stratified therapeutic&#xD;
      approach, was identified so far.&#xD;
&#xD;
      The sperm DNA fragmentation index (DFI) provides an estimation of genetic integrity of&#xD;
      spermatozoa and was shown to improve significantly after FSH treatment. Therefore, DFI could&#xD;
      be used as a pharmacodynamic marker of FSH in the male.&#xD;
&#xD;
      In women, the response to FSH varies depending on the FSH receptor (FSHR) genotype, as&#xD;
      determined by the non-synonymous SNP rs6166, which exchanges the amino acid Asn to Ser in&#xD;
      codon 680. This SNP is very common, with a minor allele frequency of 0.4. Women homozygous&#xD;
      for Ser at amino acid position 680 of the FSHR are less sensitive to endogenous and exogenous&#xD;
      FSH compared to those homozygous for Asn and require more FSH for multiple follicular growth&#xD;
      and maturation in assisted reproduction. The investigators hypothesize that the variable&#xD;
      response to FSH in unselected infertile men is due to a different individual sensitivity to&#xD;
      FSH as determined by the common FSHR polymorphism rs6166. In particular the investigators&#xD;
      will test the hypothesis that men homozygous for Asn at 680 (wild type) will respond better&#xD;
      to exogenous FSH treatment in terms of sperm DFI compared to men homozygous for Ser,&#xD;
      assessing sperm DFI as pharmacodynamic parameter of FSH.&#xD;
&#xD;
      Men with idiopathic infertility and normal serum FSH levels, candidate for treatment with&#xD;
      FSH, will be recruited. Men with a sperm DFI &gt; 15% will be included in the trial if carriers&#xD;
      of the homozygous Asn/Asn or Ser/Ser at aminoacid position 680. The FSHR genotype will be&#xD;
      assessed centrally and the physician will only receive the information whether the patient is&#xD;
      eligible for entering the trial (i.e. homozygous) but both the physician and the patient will&#xD;
      remain blind to the genotype. Human recombinant FSH (Gonal-f, Merck Serono) will be&#xD;
      self-administered sc at the dose of 150 IU every other day for 12 weeks, followed by 12 weeks&#xD;
      of observation (follow up). Changes in sperm DFI will be the primary end point and compared&#xD;
      between the two arms. In addition, the effects on pregnancy rate and other clinical and&#xD;
      hormonal parameters will be evaluated.&#xD;
&#xD;
      Should this pilot, proof-of-principle trial demonstrate that the response to FSH in male&#xD;
      idiopathic infertility depends on FSHR genotype, larger interventional trials aiming at&#xD;
      assessing the effects on pregnancy rate will be justified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sperm DFI</measure>
    <time_frame>&quot;after 12 weeks&quot;</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sperm DFI (DNA Fragmentation Index)</measure>
    <time_frame>&quot;Baseline&quot;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm DFI</measure>
    <time_frame>&quot;after 24 weeks&quot;</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>&quot;baseline&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>&quot;After 12 weeks&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>&quot;after 24 weeks&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sperm count</measure>
    <time_frame>&quot;baseline&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sperm count</measure>
    <time_frame>&quot;after 12 weeks&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sperm count</measure>
    <time_frame>&quot;after 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inhibin B</measure>
    <time_frame>&quot;baseline&quot;</time_frame>
    <description>Serum dosage</description>
  </other_outcome>
  <other_outcome>
    <measure>Inhibin B</measure>
    <time_frame>&quot;after 12 weeks&quot;</time_frame>
    <description>Serum dosage</description>
  </other_outcome>
  <other_outcome>
    <measure>Inhibin B</measure>
    <time_frame>&quot;after 24 weeks&quot;</time_frame>
    <description>Serum dosage</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-Mullerian Hormone (AMH)</measure>
    <time_frame>&quot;baseline&quot;</time_frame>
    <description>Serum dosage of Anti-Mullerian Hormone</description>
  </other_outcome>
  <other_outcome>
    <measure>AMH</measure>
    <time_frame>&quot;after 12 weeks&quot;</time_frame>
    <description>Serum dosage of Anti-Mullerian Hormone</description>
  </other_outcome>
  <other_outcome>
    <measure>AMH</measure>
    <time_frame>&quot;after 24 weeks&quot;</time_frame>
    <description>Serum dosage of Anti-Mullerian Hormone</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSHR A680G SNP homozygous for allele N treated with follitropin alpha</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSHR A680G SNP homozygous for allele S treated with follitropin alpha</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>follitropin alpha</intervention_name>
    <description>All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.&#xD;
Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage &gt; 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Gonal f</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 20-50 years&#xD;
&#xD;
          -  idiopathic male factor infertility for at least one year;&#xD;
&#xD;
          -  homozygous FSHR allele at codon 680 (wild type: Asn/Asn or Ser/Ser);&#xD;
&#xD;
          -  sperm DFI &gt; 15%;&#xD;
&#xD;
          -  normal serum FSH levels (&lt; 8 IU/L)&#xD;
&#xD;
          -  normal serum LH, testosterone, prolactin and estradiol levels&#xD;
&#xD;
          -  normal ovulatory female partner These men might have impaired ejaculate parameters&#xD;
             (decreased sperm count and/or decreased proportion of sperm with progressive motility&#xD;
             and/or decreased proportion of sperm with normal morphology) of unknown aetiology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  azoospermia&#xD;
&#xD;
          -  all known aetiologies of male infertility (endocrine disorders, genetic disorders,&#xD;
             chromosome abnormalities, congenital bilateral absence of the vas deferens,&#xD;
             microdeletions within the AZF regions of the Y chromosome, varicocele, cryptorchidism,&#xD;
             infections, immunological infertility, and obstructive infertility)&#xD;
&#xD;
          -  all known aetiologies of female infertility in the partner (tubal blockage, endocrine&#xD;
             abnormalities including anovulation and PCO, anatomical abnormalities, infections)&#xD;
&#xD;
          -  heterozygous FSHR allele at codon 680&#xD;
&#xD;
          -  drug abuse and major systemic diseases&#xD;
&#xD;
          -  testicular insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Simoni, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda USL Modena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrums für Reproduktions-medizin und Andrologie Universitätsklinikum Halle (Saale), Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ginecologia e Medicina della Riproduzione IRCCS Istituto Clinico Humanitas,</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrology Unit Department of Clinical Physiopathology</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AziendaUSLModena</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova Department of Histology, Microbiology and Medical Biotechnologies Clinical Pathology Section &amp; Centre for Male Gamete Cryopreservation</name>
      <address>
        <city>Padova</city>
        <zip>35121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Pathophysiology, University of Rome La Sapienza, Lab of Seminology &amp; Immunology of Reproduction</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda USL Modena</investigator_affiliation>
    <investigator_full_name>Manuela Simoni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

